Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells
NCT ID: NCT01357785
Last Updated: 2011-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
35 participants
INTERVENTIONAL
2011-04-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis
NCT01082822
Clinical Trials of Regeneration for Periodontal Tissue
NCT00221130
Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy
NCT02523651
Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients
NCT05924373
Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects
NCT02449005
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
According to histologic evidence, the GTR technique combined with bone graft is the most predictable regenerative procedure in the treatment of such periodontal defects, although basically, current available GTR-based therapies are still crude and of poor clinical predictability. During periodontal regenerative procedures, the remaining healthy periodontal ligament (PDL) plays a key role in the regeneration of new compartments, and the cells of PDL tissues are the only cells that seem to have the capacity to form new attachment apparatus.. The regenerative capacity of the PDL itself is attributed to a few progenitor cells maintaining their proliferation and differentiation potential in the periodontium. Recent advances in stem cell biology and regenerative medicine have presented opportunities for tissue engineering in periodontal therapy. To date, a large number of studies have reported that stem cells, in conjunction with different physical matrices and growth factors, have the capacity to regenerate periodontal tissues in vivo.
It has been demonstrated that PDL-derived progenitors are committed to several developmental lineages, i.e., osteoblastic, fibroblastic and cementoblastic. This property determines the PDL cells as a desirable cell population capable of regenerating a functional periodontal attachment apparatus. It has been shown that PDL cells may prevent ankylosis and root resorption and may possibly also produce a new PDL inserted into the tooth and adjacent bone. Moreover, roots covered with alveolar bone cells induce a cementum-like tissue formation, suggesting that cementoblast and osteoblast precursors commonly originate from the alveolar bone. Thus, PDL-derived cell sources are one of the most promising candidates for cell-based therapies and tissue-engineering-associated periodontal regeneration, and positive pre-clinical results have already been achieved both in vitro and in vivo. Taken together, the results of these investigations demonstrate that PDL cells are capable of preventing epithelial down-growth and root resorption, with the periodontal healing pattern being characterized by connective tissue adaptation involving parallel bundles resting on root dentin. The formation of new bone and cementum varies from a complete absence to coverage of parts of the debrided root surfaces mainly at the borders of the defects, to a thin layer of newly formed cementum with complete new bone formation covering the entire previously denuded root surface. The heterogeneity of results obtained may be explained by the small number of specimens used, the different types of periodontal defects observed and the stability of the carriers utilized to deliver the cells (i.e., hyaluronic acid and blood clots). In addition, one may speculate that PDL cell differentiation is highly sensitive to differences in the microenvironment, resulting in different types of periodontal healing. However, the clinical application of autologous PDL-derived cells are currently lacking.
All over the world, periodontitis remains highly prevalent, can lead loss of the affected teeth, and thus threaten quality of life for middle-aged population as far as oral functions are concerned. Unfortunately in clinic, no current periodontal treatments can, at best, heal the scar in the affected region and ever regenerate lost periodontal tissue or normal structure and functionality. Considering that the "mouth" and "teeth" have various aesthetic and functional roles to play, establishing a brand-new treatment that enables the regeneration of periodontal tissue is very important. It is clear that there is both a clinical need for such treatments and a vast patient resource. Interestingly, there is mounting data that demonstrates the induction of periodontal tissue regeneration by PDL stem cells in animal models. In particular, a number of studies show that topical administration of PDL stem cells enhances periodontal tissue regeneration in models of artificial loss of periodontal tissue in beagles and non-human primates. This suggests that PDL stem cells may be safe and effective in the regeneration of periodontal tissues in periodontitis patients.
In the phase I clinical trial for 20 healthy male volunteers by local administration of autologous PDL stem cells, neither adverse reactions nor rise of any antibody were observed (unpublished data). Importantly, several groups have commenced small-scale pilot/feasibility studies, leading sufficient information to move cell-based therapy into the clinical arena. It is therefore we established this clinical protocol to further test the efficiency and safety of stem cells in the treatment of periodontal deep intraosseous defects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cell therapy
The use of periodontal ligament stem cells for periodontal regeneration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Those who have accomplished initial preparation and have been showing good compliance
3. Those with mobility of the tooth to investigate of Degree 2 or less and with width of attached gingiva for which the existing Guided Tissue Regeneration (GTR) and bone graft implantation treatment are considered appropriate
4. Those for whom supportive periodontal treatment is applicable (the tooth has the potential to be maintain for at least 3 years), in accordance with usual post-operative procedures following flap operation and GTR treatment
5. Those whose oral hygiene is well established and who are able to perform appropriate tooth brushing and cleaning following instructions of the investigators and/or sub-investigators after investigational drug administration
6. Those 18-years-old and \<65-years-old Those who has at least one tooth (e.g. wisdom tooth) that is need to be extracted and the patient agrees the tooth extraction.
7. Those who understand the purposes of the trial and are capable of making an independent decision to comply with trial requirements
8. Those who are able to visit our hospital in accordance with the trial schedule
Exclusion Criteria
2. Those in need of administration of adrenal cortical steroid (equivalent to\>20 mg/day of Predonin) within 4 weeks after the surgery
3. Those scheduled to undergo a surgical operation in the vicinity of the tooth to investigate within 36 weeks after surgery
4. Those with coexisting mental or consciousness disorder
5. Those with coexisting malignant tumour or history of the same
6. Those with coexisting diabetes (HbA1C \>6.5%)
7. Those in an extremely poor nutritional condition (serum albumin concentration \<2 g/dL)
8. Those with 200 mL of blood drawn during the 4 weeks preceding the surgery
9. Those administered another investigational drug during the 24 h preceding investigational drug administration
10. Those with coexisting disorder of the kidney, liver, blood and/or circulatory system (Grade 2 or above)
11. Those who are either pregnant, possibly pregnant or breast-feeding, or who hope to become pregnant during the period of the trial
12. Those with a previous history of hypersensitivity to any biological active drugs
13. Those who smoke more than 10 pieces of cigarettes
14. Those who are involved in the research team of this trial
15. Others who the investigators or sub-investigators determined as unsuitable for the trial
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Air Force Military Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fa-Ming Chen
Fourth Military Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Songtao Shi, Ph.D.
Role: STUDY_DIRECTOR
School of Stomatology, Fourth Military Medical Univeristy; Ostrow School of Dentistry, University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Stomatology, Fourth Military Medical University
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chen FM, Jin Y. Periodontal tissue engineering and regeneration: current approaches and expanding opportunities. Tissue Eng Part B Rev. 2010 Apr;16(2):219-55. doi: 10.1089/ten.TEB.2009.0562.
Sonoyama W, Liu Y, Fang D, Yamaza T, Seo BM, Zhang C, Liu H, Gronthos S, Wang CY, Wang S, Shi S. Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One. 2006 Dec 20;1(1):e79. doi: 10.1371/journal.pone.0000079.
Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, Young M, Robey PG, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004 Jul 10-16;364(9429):149-55. doi: 10.1016/S0140-6736(04)16627-0.
Feng F, Akiyama K, Liu Y, Yamaza T, Wang TM, Chen JH, Wang BB, Huang GT, Wang S, Shi S. Utility of PDL progenitors for in vivo tissue regeneration: a report of 3 cases. Oral Dis. 2010 Jan;16(1):20-8. doi: 10.1111/j.1601-0825.2009.01593.x.
Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, Gronthos S, Shi S, Wang S. Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine. Stem Cells. 2008 Apr;26(4):1065-73. doi: 10.1634/stemcells.2007-0734. Epub 2008 Jan 31.
Fang D, Seo BM, Liu Y, Sonoyama W, Yamaza T, Zhang C, Wang S, Shi S. Transplantation of mesenchymal stem cells is an optimal approach for plastic surgery. Stem Cells. 2007 Apr;25(4):1021-8. doi: 10.1634/stemcells.2006-0576. Epub 2006 Dec 14.
Park JC, Kim JM, Jung IH, Kim JC, Choi SH, Cho KS, Kim CS. Isolation and characterization of human periodontal ligament (PDL) stem cells (PDLSCs) from the inflamed PDL tissue: in vitro and in vivo evaluations. J Clin Periodontol. 2011 Aug;38(8):721-31. doi: 10.1111/j.1600-051X.2011.01716.x. Epub 2011 Mar 30.
Krasner P, Verlander P. Stem cells in dentistry and medicine: the dentist's role. Dent Today. 2011 Jan;30(1):128, 130-4; quiz 135.
Simsek SB, Keles GC, Baris S, Cetinkaya BO. Comparison of mesenchymal stem cells and autogenous cortical bone graft in the treatment of class II furcation defects in dogs. Clin Oral Investig. 2012 Feb;16(1):251-8. doi: 10.1007/s00784-010-0486-7. Epub 2010 Nov 18.
Yang Y, Rossi FM, Putnins EE. Periodontal regeneration using engineered bone marrow mesenchymal stromal cells. Biomaterials. 2010 Nov;31(33):8574-82. doi: 10.1016/j.biomaterials.2010.06.026. Epub 2010 Sep 15.
Washio K, Iwata T, Mizutani M, Ando T, Yamato M, Okano T, Ishikawa I. Assessment of cell sheets derived from human periodontal ligament cells: a pre-clinical study. Cell Tissue Res. 2010 Sep;341(3):397-404. doi: 10.1007/s00441-010-1009-1. Epub 2010 Jul 15.
Iwata T, Yamato M, Zhang Z, Mukobata S, Washio K, Ando T, Feijen J, Okano T, Ishikawa I. Validation of human periodontal ligament-derived cells as a reliable source for cytotherapeutic use. J Clin Periodontol. 2010 Dec;37(12):1088-99. doi: 10.1111/j.1600-051X.2010.01597.x.
Yang ZH, Jin F, Zhang XJ, Liu X, Zhang YF, Liu JQ, Duan YZ, Jin Y. A novel possible strategy based on self-assembly approach to achieve complete periodontal regeneration. Artif Organs. 2010 Jul;34(7):603-9. doi: 10.1111/j.1525-1594.2009.00991.x. Epub 2010 Jun 10.
Wei N, Gong P, Liao D, Yang X, Li X, Liu Y, Yuan Q, Tan Z. Auto-transplanted mesenchymal stromal cell fate in periodontal tissue of beagle dogs. Cytotherapy. 2010 Jul;12(4):514-21. doi: 10.3109/14653241003709702.
Chen FM, Gao LN, Tian BM, Zhang XY, Zhang YJ, Dong GY, Lu H, Chu Q, Xu J, Yu Y, Wu RX, Yin Y, Shi S, Jin Y. Treatment of periodontal intrabony defects using autologous periodontal ligament stem cells: a randomized clinical trial. Stem Cell Res Ther. 2016 Feb 19;7:33. doi: 10.1186/s13287-016-0288-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.